Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • COVID-19
    • COVID-19 Update
    • Evaluate Vantage COVID-19 Report
    • COVID-19 Stories from Evaluate Vantage
    • Evaluate’s Business Continuity Plan
  • What We Do
    • Commercial Intelligence
    • Products
      • EvaluatePharma
      • Evaluate Omnium
      • Japan Drug Forecasts
      • European Drug Forecasts
      • Epi Analyzer
    • Evaluate Custom Solutions
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Data Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
  • How We Can Help You
    • Pharma and Biotech
    • Medtech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
    • Careers
      • Current Vacancies
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Data Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Active Biotech

Thumbnail
June 11, 2020

New Genmab/Abbvie tie-up rings old bells

Followers of Nordic Nanovector and Oxford Biomedica, among others, will pay close attention to an early focus of yesterday’s deal.

Thumbnail
October 18, 2018

From zero to hero, Endocyte completes a remarkable transformation

The US biotech claims an unexpected victory, scoring a $2.1bn takeover by Novartis on the strength of an asset it had bought for just $12m.

Vantage logo
May 12, 2017

Snippet roundup: Sighs of relief for Astra and Glaxo

Vantage logo
August 03, 2016

Therapy focus – One step forward but two steps back in Huntington’s

Vantage logo
January 05, 2016

The sun sets on laquinimod

Vantage logo
September 11, 2015

Upcoming events: Readouts could mean an IPO for Afferent and a licence for Bavarian

Vantage logo
June 05, 2015

Roche on the wrong side for once in shifting analyst forecasts

Vantage logo
April 16, 2015

Development can be a thankless tasq in post-Xtandi world

Vantage logo
January 08, 2015

Buoyant small pharma market hides some big losers

Vantage logo
July 03, 2014

Market wobble fails to derail mid and small-caps

Vantage logo
April 28, 2014

Event – Active Biotech faces a hard tasq

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

December 10, 2020

Evaluate Vantage 2021 Preview

July 29, 2020

Evaluate Vantage Pharma, Biotech & Medtech Half-Year Review 2020

View more...

Editor's Picks

Vantage logo
January 18, 2021

Aducanumab tops 2021’s biggest potential launches

Vantage logo
January 19, 2021

The pandemic releases its grip on clinical trials

Vantage logo
January 21, 2021

2020 drug approvals rise despite Covid-19

Vantage logo
January 20, 2021

Glaxo joins the Covid-19 delay queue

Vantage logo
January 21, 2021

Merck KGaA’s dual immuno-oncology weapon misfires

Open modal

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)80-1164-4754

Footer menu

  • Terms and Conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2021 Evaluate Ltd.